 |
 |
 |
 |
 |
Treatment Name: |
 |
Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma |
 |
 |
 |
 |
Phase: |
 |
Phase 1/2 |
 |
 |
 |
 |
 |
 |
Treatment ID#: |
 |
1805 NABTC 05-02 |
 |
 |
 |
 |
Age Group: |
 |
Adults Only |
 |
 |
 |
 |
 |
 |
Min Karnofsky Score: |
 |
60: Requires occasional assistance but is able to care for most of own needs |
 |
 |
 |
 |
Conditions: |
 |
Prior Surgery is Allowed Prior Radiation is Allowed Prior Chemotherapy is Allowed Recurrent Glioblastoma Multiforme or Gliosarcoma |
 |
 |
 |
 |
 |
 |
Last Updated: |
 |
04/15/2008 |
 |
 |
 |
 |
Tumor Types: |
 |
Glioblastoma Multiforme Gliosarcoma |
 |
 |
 |
 |
 |
 |
 |
Comments: |
 |
BAY 43-9006 (sorafenib) blocks the vascular endothelial growth factor receptor (VEGF-R) and a protein in an important tumor growth pathway (B-raf). CCI-779 (temsirolimus) blocks a specific protein, mTOR, which is important in pathways that promote tumor growth. R115777 (tipifarnib) blocks an important process called farnesylation that activates proteins for several important tumor growth pathways. OSI-774 (erlotinib) blocks the epidermal growth factor receptor (EGF-R). Combining two drugs that block these factors and receptors may provide better tumor control than a single drug. This study will also determine the relationship between biomarkers in the tumor and patient`s blood with patient response. |
 |
 |
 |
 |
 |
 |
Treatment Type: |
 |
Less-Toxics Immunological, Biological or Targeted Therapy |
 |
 |
 |
 |
Contact: |
 |
Clinical Trials Office - Dana-Farber/Harvard Cancer Center Dana-Farber/Harvard Cancer Center Dana Farber Cancer Institute
Boston, MA 02115 USA Phone: 617-582-8480 Fax: E-mail: Website: |
 |
 |